進行した二次性副甲状腺機能こう進症に対するｍａｘａｃａｌｃｉｔｏｌ副甲状腺内直接注入療法の効果―ＰＴＨ抑制の評価と予測因子としてのｗｈｏｌｅ　ＰＴＨ―

DOI

書誌事項

タイトル別名
  • Clinical effect of percutaneous maxacalcitol injection therapy on advanced secondary hyperparathyroidism-The predictive value of whole PTH assay-
  • The predictive value of whole PTH assay
  • PTH抑制の評価と予測因子としてのwhole PTH

抄録

Percutaneous maxacalcitol (OCT) injection therapy (PMIT) has been developed as an effective and safe treatment for advanced secondary hyperparathyroidism (SHPT). The effect of PMIT on PTH suppression was evaluated by intact PTH, highly sensitive (HS) PTH, and whole PTH assays.<br>Eight dialysis patients with SHPT resistant to intravenous OCT administrations were consecutively treated by PMIT six times a week followed by OCT intravenous administrations (iv OCT). Serum intact PTH, HS PTH, whole PTH, Ca adjusted for albumin, and P levels were measured before, immediately, 4 and 12 weeks after PMIT.<br>After PMIT, serum intact PTH, HS PTH, and whole PTH levels were significantly decreased, however serum adjusted Ca and P levels did not change significantly. Whole PTH/C PTH (calculated by intact-PTH-whole PTH) ratio was also significantly decreased immediately after PMIT. In five patients whose PTH levels were controlled by iv OCT for more than 6 months after PMIT (effective group), the decrease in whole PTH level after PMIT was significantly greater compared with that in the ineffective group whose PTH levels could not be controlled by iv OCT.<br>It is suggested that whole PTH difference immediately after PMIT compared to that before may predict the effect of PMIT.

収録刊行物

キーワード

詳細情報 詳細情報について

  • CRID
    1390001204677003392
  • NII論文ID
    130003875233
  • DOI
    10.4009/jsdt.37.1311
  • ISSN
    1883082X
    13403451
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • Crossref
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ